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Abstract
Background: Use of immunosuppressant drugs has been associated with complications in wound healing. The
calcineurin inhibitor tacrolimus is thought to have a relatively low complication rate, but preclinical research has
yielded contradictory data, prompting the current comprehensive study
Methods: Three groups of 33 male Wistar rats received a daily subcutaneous dose of 0,5, 2 or 5 mg/kg tacrolimus. A
control group received saline. On day 0 a resection of 1 cm ileum and 1 cm colon was performed, and end-to-end
anastomoses were constructed. Ten rats of each group were killed on day 3 and day 5 and the remaining animals on
day 7. Both anastomoses and the wound in the abdominal wall were analyzed. Wound strength was the primary
outcome parameter.
Results: Mean strength of the abdominal wall increased significantly over time in all groups (p<0.0001). Both the
breaking strength and the bursting pressure of the ileum and colon anastomoses followed the same pattern. No
differences were observed between control and experimental groups. In addition, no consistent differences were
found between groups regarding wound hydroxyproline content and the activities of matrix metalloproteinase-2 and
-9.
Conclusion: Tacrolimus does not affect early wound healing.
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Introduction
Under different immunosuppressant regimes, wound healing
disturbances are seen in 7-53% of kidney transplant recipients
[1-4]. The premise that all immunosuppressant drugs have a
negative effect on wound healing is widely accepted, although
often scientific proof is lacking or inadequate. Clinical studies
almost invariably use a regime of several immunosuppressant
drugs, making it difficult to attribute adverse effects to a single
component [4,5]. Thus, preclinical research is necessary to
elucidate potential effects of individual drugs. This way we
have demonstrated that everolimus, a m-TOR inhibitor, has a
negative, dose- and time-dependent effect on experimental
wounds in intestine and abdominal fascia [6,7].
Today, the typical standard regime of immunosuppressant
drugs in solid organ transplantation consists of a calcineurin
inhibitor such as cyclosporin or tacrolimus, an antiproliferative
agent (azathioprine or mycophenolate mofetil) and a steroid. In
this regime, tacrolimus is the newer agent, and extensive
research has been carried out to establish its benefit over
cyclosporine [1,8-10]. In contrast to most immunosuppressive
drugs, tacrolimus, a macrolide derived from the fungus S
tsukubaensis, is believed to have few or none adverse effects
on wound healing. Still, as a calcineurin inhibitor, tacrolimus
affects the first phase of T-cell activation. Because
inflammatory T cells play a role in wound healing an effect of
tacrolimus on wound healing is conceivable. Reported effects
of tacrolimus in preclinical studies are contradictory, ranging
from stimulation to inhibition of soft tissue repair [11-16]. A
common drawback to these studies is the fact that, almost
without exception, only one post-operative time point is
evaluated, while wound healing is a complex process with
different and overlapping phases.
The present comprehensive study has been performed to
evaluate the effects of tacrolimus, used as a single drug in
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three different doses, and at multiple time points during healing
of bowel anastomoses and abdominal fascia in rats.
Materials and Methods
One hundred thirty-two male Wistar rats (body weight
240-260 g; Harlan, Horst, The Netherlands) were randomly
divided into four groups of thirty-three animals. The animals
were housed two per cage and allowed to become accustomed
to laboratory conditions for one week before the start of the
experiment. All animals had free access to water and standard
rodent chow (Ssniff Specialdiäten GmbH, Soest, Germany).
Three groups received tacrolimus (Prograft®, Astellas,
Killorglin, Ireland) subcutaneously in daily dosages of 0.5
(group T0.5), 2.0 (group T2) and 5.0 (group T5) mg/kg/day
from the day of operation until the end of the experiment. A
control group received saline subcutaneously.
Ethic Statement
This study was carried out in strict accordance with the
National Dutch Act on Experimental Animals. The protocol
(80320) was approved by the Animal Ethics Review Committee
of the Radboud University, Nijmegen (Permit number
DEC-2008-114). In order to minimize suffering all surgery was
performed under general anesthesia using isoflurane 3%, in a
mixture of oxygen and nitrous oxide. Postoperative analgesia
was performed with buprenorphine, 0.02 mg/kg
subcutaneously, twice daily for two days. The animals were
killed by CO2/CO asphyxiation to reduce as much stress as
possible. An individual animal welfare logbook was kept and
reported back to the Animal Ethics Review Committee.
Surgical Procedure
On day 0, a midline laparotomy was performed and followed
by a resection of 1 cm ileum 15 cm proximal to the ileocaecal
junction and 1 cm colon 3 cm proximal to the rectal peritoneal
reflection. End-to-end anastomoses were constructed with
eight single-layer, inverting, interrupted 8-0 ethilon (Ethicon)
sutures. The abdominal fascia was closed with an absorbable,
polygalactin 3-0 suture, the skin was closed with staples. A
heating pad was used to maintain body temperature at 38°C.
The intestines were covered with gauze pads soaked with
0.9% NaCl to minimize desiccation. Fluid loss was
compensated by administering 10 ml of 0.9% subcutaneously
direct postoperative. The animals were weighed daily and
observed for signs of illness. All operative procedures were
performed by the same investigator (MW).
Wound strength
Ten rats per group were killed on day 3 and day 5 each, and
the remaining animals were killed on day 7. In the latter group,
EDTA whole blood was sampled for tacrolimus assay (see
below). Relaparotomy was performed by excision of a part of
the abdominal wall of approximately 4 by 4 cm, including the
suture line of the fascia. The anastomoses of ileum and colon
were resected with adjacent bowel of approximately 4 cm in
length and the suture line in the middle. The intestinal
segments were carefully resected, including surrounding
tissues and adhesions, and washed in saline. Bursting
pressure and breaking strength were measured in the same
segment as described previously [17]. In the abdominal wall
the breaking strength was measured in the same way; from
each segment of the abdominal wall, two separate strips of 1
by 2 cm were collected, with the suture line in the middle, and
the breaking strength was measured in both. After
biomechanical analysis, segments were cleaned from adhering
tissue and standard sized samples containing the suture line
were frozen in liquid nitrogen and stored at -80°C until further
processing.
Biochemical analysis and histology
After lyophilisation, tissue samples were weighed,
pulverized, and lyophilized again. Both hydroxyproline content
and gelatinase activity were measured in control, T2 and T5
groups. The hydroxyproline content, as a measure of the
collagen content, was measured by high-performance liquid
chromatography after hydrolysis with 6-N-hydrochloric acid and
derivatization with dabsyl-chloride.
Preparation of tissue extracts and procedures for gelatin
zymography have been described previously [18]. The protein
concentration of the extracts was measured using the
bicinchoninic acid reagent. The various gelatinase activities
were quantitated on the basis of lysed area and expressed as
arbitrary units. Comparison of values obtained on different gels
was performed by using collagenase type I (from Clostridium
histolyticum; Sigma Chemical) as an internal standard. The
presence of true matrix metalloproteinase (MMP) activity was
confirmed by adding 10 mmol/L EDTA or 1,10 phenanthrolene
to the buffers used after electrophoresis. Tacrolimus in whole
blood was assayed using a PRO-TracTM ELISA kit from
DiaSorin (Still water, Minnesota, USA). Sections of
anastomoses originating from separate animals in the groups
sacrificed after 7 days that had not been subjected to strength
measurements were washed in 0.9% NaCl, spread out, and
fixed immediately in a 4% phosphate-buffered formaldehyde
solution. Subsequently, the samples were dehydrated and
embedded in paraffin blocks. Sections of 4 mm in thickness
were stained with hematoxylin and eosin (H&E).
Statistical analysis
To analyze differences in body weight and MMP-activity a
Kruskal Wallis followed by Dunn’s test was used. Data of
breaking strength, bursting pressure and hydroxyproline
content were analysed with ANOVA followed by Tukey-Kramer
post test.
Results
The mean trough level of tacrolimus, as measured in whole
blood collected on day 7 after operation, was 0.3 ± 0.2 (SD)
ng/ml in the control group and 4.9 ± 2.4, 10.1 ± 2.0 and 12.3 ±
5.6 ng/ml, respectively, in the T0.5, T2 and T5 groups.
Eight animals died prematurely or were taken out of the
experiment because of poor health: one each in the control and
T0.5 groups (ileus), two in the T2 group (unknown reasons and
excessive weight loss, respectively) and four in the T5 group
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(two after excessive weight loss and two of unknown reasons).
Diarrhea, observed at least once during the experiment, was
found in one thirty-second of the surviving rats in the control
group and in 0/32, 2/31 and 7/29 (p=0.022) in the T0.5, T2 and
T5 groups, respectively.
All animals experienced a transient weight loss of
approximately 10-15% of their body weight. From day 4
onwards they regained weight, those in the control group
approximating their pre-operative weight at day 7 (Figure 1).
However, the weight gain in animals receiving tacrolimus was
less than in the control group. The relative weight in all
experimental groups at day 7 was significantly (p<0.05) lower
than in the control group.
Wound strength
Individual values for anastomotic bursting pressures in the
intestine are given in Figure 2. They increased with time from
day 3 onwards and, at all time points, median values were
comparable in all four groups. From day 5 the bursting site was
increasingly frequent outside the true anastomotic area (Table
1). An increase in the number of anastomoses bursting outside
the suture line represents an increase in anastomotic strength.
Altogether, this phenomenon occurred equally frequent in
control and tacrolimus groups.
Wound breaking strength is depicted in Figure 3. After 3
days fascia strength was very low but increased rapidly
thereafter. For all groups, the gain in fascia strength was very
Figure 1.  Postoperative course of body weight.  Points represent average relative body weight, in relation to the weight prior to
operation, for the control group (□) and the groups receiving tacrolimus: T0.5 (◼), T2 (Δ) and T5 (●).
doi: 10.1371/journal.pone.0076348.g001
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significant (comparison of values at 3, 5 and 7 days by
ANOVA: p<0.0001) and similar. At no time there were
significant differences between the four groups. For the
intestinal anastomoses, the gain in strength between day 3 and
day 5 was less explicit. Still, for all groups anastomotic strength
increased significantly (p<0.05) with time, values at day 7
always being higher (Tukey-Kramer, p<0.05) than those at day
3. A significant difference between groups was only found for
ileal anastomoses at day 7 where strength was higher in the T5
group than in the control group. Breaking always occurred
within the suture line.
Wound collagen content and gelatinase activity
Wound hydroxyproline, as a measure for collagen content is
given in Figure 4. Generally speaking, it increased with time,
values at day 7 almost invariably being significantly (p<0.05)
higher than those at day 3. In ileum, there were no differences
between controls and experimental groups. In colon, values in
the T5 group were lower than in the T2 group but equivalent to
those in controls. In fascia, the hydroxyproline content was
highest in the T5 groups.
The results of the zymographic measurements of gelatinase
activity, in ileal and colonic tissue at day 3 and 7, are
summarized in Figure 5. The activities of proMMP-9 and
proMMP-2 were similar in control and tacrolimus groups.
Although MMP-9 activities were low and varied considerably
between animals, they appeared higher in the tacrolimus
groups, especially in ileum. For MMP-2, differences were seen
in colon where tacrolimus apparently lowered activity at day 3
while increasing it after 7 days.
Histology
A comprehensive examination of sections obtained from
controls and the T0.5 and T2 groups failed to reveal any
obvious architectural differences at day 7. Semiquantitative
analysis also failed to indicate any differences between control
Figure 2.  Anastomotic bursting pressure.  Individual values and medians (horizontal lines) in ileum and colon. A,B,C = ileum 3,5
and 7 days postoperative. D,E,F = colon 3, 5 and 7 days postoperative. X-axis: study groups. Open symbols denote rupture outside
the suture line and closed symbols rupture inside the suture line.
doi: 10.1371/journal.pone.0076348.g002
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and the tacrolimus groups with respect to histologic parameters
such as mucosal repair, epithelial damage, wound area
surface, degree of necrosis, and cellular infiltration.
Discussion
Although clinical studies of the effects on wound healing of
single immunosuppressive drugs are lacking, wound
complications after solid organ transplantation are often
attributed to these drugs. Regimes including rapamycin
derivates have been shown to be associated with more wound
complications than those with calcineurin inhibitors. Our earlier
experimental studies demonstrated a profound negative effect
of everolimus on wound healing in the rat [6,7]. The present
data clearly show that tacrolimus has no such effect and that
surgical wounds demonstrate normal repair in the critical first
week after operation, even during administration of doses
leading to high trough levels of the drug. There is also no
evidence for improvement of wound healing with tacrolimus.
Calcineurin inhibitors are notoriously known for their chronic
toxicity and consequent chance of graft loss. Although
cyclosporine and tacrolimus essentially inhibit the action of
calcineurin in the same way, their side effects differ slightly.
Tacrolimus is superior to cyclosporine in preventing acute
rejection and improving graft survival which has resulted in an
enormous increase in use of the agent since introduction in
1989 [10]. Tacrolimus has a greater effect on impairing the
expression of alloantigen stimulated T-lymfocytes than does
cyclosporine [19] but supposedly a less significant effect on
wound healing. Clinically, it is always used together with other
drugs, therefore, its safety in terms of interference with wound
repair must be assessed in a preclinical model.
Preclinical data on the effects of tacrolimus on wound
healing are few and contradictory. Doses of 2 mg/kg/day
reportedly inhibit skin healing, but not colonic or ileal
anastomotic healing [11,12,14,15]. Kiyama et al. even found
that low doses (0.01-1 mg/kg/day) increased wound strength in
the colon but not in the ileum [13]. In all these experimental
Table 1. Anastomotic bursting site.
  Ileum Colon  
 C 0/10 0/10  
Day 3 T0.5 0/10 0/10  
 T2 0/9 0/10  
 T5 1/10 0/10  
 C 0/9 7/9  
Day 5 T0.5 2/10 4/10  
 T2 5/10 8/9  
 T5 0/10 4/10  
 C 3/9 6/10  
Day 7 T0.5 5/9 8/9  
 T2 2/9 8/9  
 T5 8/9 6/9  
Numbers represent the frequency of the bursting site being without the actual
suture line.
doi: 10.1371/journal.pone.0076348.t001
studies wound repair was analyzed at one time point only.
Raptis et al. also used a low tacrolimus dose of 0.1 mg/kg/day
and reported evidence of enhanced rodent colonic anastomotic
healing, measured as bursting pressure at 4 and 8 days
postoperatively [16].
In order to obtain data which would allow a comprehensive
analysis of the possible effects of tacrolimus on soft tissue
repair we analyzed wounds in intestine and abdominal fascia.
Tacrolimus was administered in three doses which, dose-
dependently, led to trough levels ranging from 5 to 12 ng/ml.
These levels are in the range often reported in clinical studies
[20]. Finally, the study included three time points, covering the
inflammatory and early proliferative phases of the healing
sequence. The first week after operation is particularly
important because wound strength remains low during the first
few days and increases from day 3 onwards. Any interference
in this period will enhance chances on wound dehiscence.
The results presented here are unambiguous. Tacrolimus, in
three different clinically relevant dosages, does not interfere
with and does not promote wound strength, which is the
primary functional outcome parameter. This result holds for
wounds in both small and large bowel and in the abdominal
fascia at any of the three time points measured. For the bowel
anastomoses, we measured two independent parameters for
strength, the bursting pressure and the breaking strength. The
bursting pressure, which represents the ability to withstand
intraluminal pressure, only reflects wound strength if the
bursting site is within the suture line which will not always be
the case after day 3. Therefore, it is very relevant to collect
additional data for the breaking strength, which reflects wound
strength over the entire period analysed here. Interestingly,
undisturbed healing proceeded despite the fact that the rats in
the experimental groups were clearly in a more catabolic state
than those in the control group (Figure 1).
The introduction of new immunosuppressant agents has
increased graft survival. However, at the same time, long term
complications not related to graft function, become increasingly
important, much of them due to development of cardiovascular
disease or malignancies, related to the use of
immunosuppressant drugs. The proportion of deaths attributed
to malignancy in the first decade after transplantation is as high
as 26% and rising [21]. Presumably, this phenomenon will
result in a rise in future operations not related to the
transplanted organ. Surgery needs to be executed under
immunosuppressant therapy, possibly with increased chances
of wound complications such as bowel leakage or incisional
hernia. The present data emphasize the fact that tacrolimus,
contrary to other drugs used for immunosuppression, does not
have a negative effect on wound healing. This may be of
clinical consequence in the direct post-transplant phase, as
well as in patients on immunosuppressant therapy that have to
undergo surgical procedures for other reasons. Such
knowledge, obtained from preclinical studies as the present
one, is very relevant for determining an optimal
immunosuppressant regime in terms of composition, timing and
dosage.
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Figure 3.  Wound breaking strength.  Data represent mean and SEM in the control groups (white bars) and the T0.5 (black &
white bars), T2 (grey bars) and T5 (black bars) tacrolimus groups. A= ileum anastomoses, B= colon anastomoses, C = fascia.
doi: 10.1371/journal.pone.0076348.g003
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Figure 4.  Wound hydroxyproline content.  Data are expressed as hydroxyproline content per 5 mm tissue length and represent
mean and SEM for the controls (white bars) and the T2 (grey bars) and T5 (black bars) tacrolimus groups. A= ileum, B= colon, C =
fascia. *: p<0.05 vs T2 group; #: p<0.05 vs control group.
doi: 10.1371/journal.pone.0076348.g004
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Figure 5.  MMP activity in intestinal anastomoses.  Columns represent mean values + SEM for controls (white bars) and the T2
(grey bars) and T5 (black bars) tacrolimus groups. Data represent total activities, in arbitrary units, per 5-mm segment for proMMP-9
(A), MMP-9 (B), proMMP-2 (C), and MMP-2 (D). *: p<0.05 vs control group.
doi: 10.1371/journal.pone.0076348.g005
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Conclusion
Tacrolimus, as a single drug, does not influence the repair
sequence in soft tissues during the first week after operation.
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